Significance of Cannabinoid CB1 Receptors in Improgan Antinociception
- 30 November 2007
- journal article
- Published by Elsevier BV in The Journal of Pain
- Vol. 8 (11), 850-860
- https://doi.org/10.1016/j.jpain.2007.05.015
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Antinociceptive activity of chemical congeners of improgan: Optimization of side chain length leads to the discovery of a new, potent, non-opioid analgesicNeuropharmacology, 2006
- Inhibitory effects of CB1 and CB2 receptor agonists on responses of DRG neurons and dorsal horn neurons in neuropathic ratsEuropean Journal of Neuroscience, 2005
- Evidence that (−)-7-hydroxy-4′-dimethylheptyl-cannabidiol activates a non-CB1, non-CB2, non-TRPV1 target in the mouse vas deferensNeuropharmacology, 2005
- Inverse agonism and neutral antagonism at cannabinoid CB1 receptorsLife Sciences, 2005
- Synthesis, Structure−Activity Relationship, and Evaluation of SR141716 Analogues: Development of Central Cannabinoid Receptor Ligands with Lower LipophilicityJournal of Medicinal Chemistry, 2003
- Inhibition of Improgan Antinociception by the Cannabinoid (CB)1 AntagonistN-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A): Lack of Obligatory Role for Endocannabinoids Acting at CB1 ReceptorsJournal of Pharmacology and Experimental Therapeutics, 2002
- Novel, Not Adenylyl Cyclase-Coupled Cannabinoid Binding Site in Cerebellum of MiceBiochemical and Biophysical Research Communications, 2002
- Evidence of a novel site mediating anandamide-induced negative inotropic and coronary vasodilatator responses in rat isolated heartsBritish Journal of Pharmacology, 2002
- Mesenteric Vasodilation Mediated by Endothelial Anandamide ReceptorsHypertension, 1999
- Biochemical and pharmacological characterisatioN OF SR141716A, the first potent and selective brain cannabinoid receptor antagonistLife Sciences, 1995